Transforming Canadians’ lives
Partnering to champion policies that drive the discovery, development and delivery of transformative medicines and vaccines.
Access to Medicine
Timely access to new medicines saves lives, improves health outcomes, helps reduce healthcare costs, contributes to economic productivity, and makes […]
Drugs for Rare Diseases (DRD)
One in 12 Canadians, two-thirds of them children, suffer from a rare disease. IMC is committed to advocating for policies […]
BENEFITS OF INNOVATIVE MEDICINES
Real hope for patients and families
New medicines and vaccines save lives and help make our healthcare system more cost‑effective.
Preventing or curing disease means extending lives, relieving suffering and improving people’s quality of life.
Promoting a robust regulatory protocol means ensuring safe and effective medicines for Canadians.
Supporting sustainable healthcare means we all spend more time enjoying life and being productive.
Industry impact In Canada
Better Health Outcomes
Innovative Medicines Canada members
Yearly economic impact
Ontario PreBudget Submission
Ensuring timely access and availability of innovative medicines and vaccines is a critical component. Not only will this support important provincial patient needs, it will also create an environment which is more open to future healthcare research and investment.
Increasing Access to Innovative Medicines
The impact of the COVID-19 pandemic has shifted the health landscape in Canada. While the federal government has demonstrated its ability to react to an unprecedented health crisis, doing so has also sharpened the focus on domestic capacity and innovation in the life sciences sector.
Throughout the pandemic, we could not be prouder of our members’ collaborative efforts worldwide. From the onset, they worked toward agreements with nations and competitors to increase manufacturing capacity and minimize pharmaceutical supply chain disruption. IMC members demonstrated the industry’s value to the world, as the critical importance of reliable access to medicines was brought into focus.
Alberta Budget Submission 2023
Innovative Medicines Canada (IMC) is the national association representing Canada’s innovative pharmaceutical industry. The association advocates for policies that promote the discovery, development and delivery of innovative medicines and vaccines to improve the lives of all Canadians. In addition, it supports the commitment of its members as valued partners in the Canadian healthcare system.
The association represents 50 companies, which invest nearly $1.4 billion annually in research and development. In this way, it nurtures a high value-added knowledge economy while contributing $8 billion to the national economy.
The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals
Innovative Medicines Canada has submitted formal feedback to the Patented Medicine Prices Review Board’s (PMPRB) revised Draft Guidelines public consultation, calling for a suspension of the planned implementation to ensure meaningful stakeholder consultation and a thorough impact analysis.
Innovative Agreements Framework
Many products coming to market are poorly served by traditional negotiation approaches. This document describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework.
Canadian Drug Access Pathway
The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (732 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).
LATEST PRESS RELEASES
Press Release March 22, 2023
Drugs for rare diseases announcement is a step forward for patients
Ottawa, March 22, 2023 – Innovative Medicines Canada (IMC) is encouraged by the federal government’s announcement regarding its intentions for […]
Press Release February 14, 2023
A National Rare Disease Strategy Could Change Patients’ Lives
Ottawa, February 14, 2023 – With Rare Disease Day fast approaching, the federal government has an opportunity to make a […]
Press Release February 01, 2023
Appointment of PMPRB chair offers opportunity for meaningful stakeholder engagement
Ottawa, ON – Innovative Medicines Canada (IMC) welcomes the new leadership of the Patented Medicine Prices Review Board (PMPRB) with […]
Press Release December 19, 2022
an Opportunity for Meaningful Consultation
Ottawa, ON – Innovative Medicines Canada (IMC) welcomes the Patented Medicine Prices Review Board (PMPRB) announcement to delay the implementation […]
Press Release December 15, 2022
PMPRB leadership issues heighten need to suspend implementation of the revised draft Guidelines
Ottawa, ON – Following the resignation of the Patented Medicine Prices Review Board’s (PMPRB) Acting Chairperson last week, Innovative Medicines […]
Press Release December 05, 2022
Innovative Medicines Canada calls for a suspension of the PMPRB’s revised Draft Guidelines
Ottawa, ON – Innovative Medicines Canada (IMC) has submitted formal feedback to the Patented Medicine Prices Review Board’s (PMPRB) revised […]
Press Release November 22, 2022
PMPRB Continues to Mislead Canadians on the Value of Innovative Medicines
Ottawa, ON – Innovative Medicines Canada (IMC) is once again disappointed by the inaccurate and misleading information on the value […]
Featured News November 15, 2022
Health Research Foundation Announces Recipient of its Medal of Honour
Ottawa, ON – The Health Research Foundation (HRF) of Innovative Medicines Canada is pleased to announce that Dr. Allison McGeer […]